Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Alaunos Therapeutics Inc TCRT

Healthcare Biotechnology

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity... see more

Add To Watchlist

Recent & Breaking News (NDAQ:TCRT)

25 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com June 22, 2017

Breakfast Technical Briefing on Biotech Stocks -- CytRx, Keryx Biopharma, TG Therapeutics, and ZIOPHARM Oncology

PR Newswire June 22, 2017

Mid-Afternoon Market Update: Fang Drops After Q1 Results; Invivo Therapeutics Shares Surge

Benzinga.com June 20, 2017

ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting

GlobeNewswire June 5, 2017

ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference

GlobeNewswire June 2, 2017

ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting

GlobeNewswire May 17, 2017

ZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock

GlobeNewswire May 12, 2017

ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia

GlobeNewswire May 2, 2017

ZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities

GlobeNewswire May 1, 2017

Investor Network: ZIOPHARM Oncology, Inc. to Host Earnings Call

Accesswire May 1, 2017

ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1, 2017 at 4:30 p.m. ET

GlobeNewswire April 24, 2017

ZIOPHARM Oncology to Present Updated Clinical Results of Gene Therapy Candidate Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting

GlobeNewswire April 20, 2017

Biotech Stocks Under Scanner -- Biostage, Keryx Biopharma, Kite Pharma, and ZIOPHARM Oncology

PR Newswire April 20, 2017

Intrexon, ZIOPHARM and Merck KGaA, Darmstadt, Germany Advancing Next-Generation Non-Viral CAR-T Platform Empowered by Membrane-Bound IL-15 Under RheoSwitch Therapeutic System® Control

GlobeNewswire April 3, 2017

Mid-Day Market Update: Dow Falls 80 Points; Cellect Biotechnology Shares Spike Higher

Benzinga.com March 27, 2017

ZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in Recurrent Glioblastoma

GlobeNewswire March 27, 2017

ZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications

GlobeNewswire March 27, 2017

Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results

PR Newswire March 1, 2017

Technical Reports on Biotech Stocks -- ZIOPHARM Oncology, Aurinia Pharma, Arena Pharma, and Marinus Pharma

PR Newswire February 28, 2017

ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing “Point-of-Care” Approach

GlobeNewswire January 31, 2017